October 14, 2020 5:21pm

Everyone has an opinion, back it up with facts

Pre-open indication results: 1 HIT and 2 MISS

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't.

Subscription is coming, my gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

The Dow closed DOWN -165.81 points (-0.58%), the S&P closed DOWN -23.26 points (-0.66%) while the Nasdaq closed DOWN – 95.17points (-0.80%)

 

Henry’omics:

Indexes fell on Wednesday, giving back an earlier gain, after comments from Treasury Secretary Mnuchin dampened expectations of a deal being reached on new coronavirus aid as both sides were still far apart on certain issues.

Despite Tuesday’s and Wednesday’s declines, stocks are higher for October, with the Dow up 2.6% including the S&P 500 (+3.7%) and the Nasdaq 5.4%.

 

This morning, I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: uncertainty accentuates risk, headlines spook the markets and investors” … https://www.regmedinvestors.com/articles/11588

 

Pre-open indications: 1 HITs < SELL into Strength: Ultragenyx (RARE -$4.71), and 2 MISS < Biostage (BSTG +$0.02), bluebird bio (BLUE -$0.96)>

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Wednesday opened positive at 22/10 and 3 flats, strayed negative at the mid-day at 15/18 and 2 flats, closing negative at 11/22 and 2 flats;
  • Tuesday opened negative at 15/18 and 2 flats, stayed negative at the mid-day at 14/17 and 4 flats, closing positive at 20/12 and 3 flats;
  • Monday opened negative at 10/22 and 3 flats, stayed negative at the mid-day at 14/18 and 3 flats, closing neutral at 16/16 and 3 flats;

 

Key metrics:

  • Sector volume was the usual LOW with 5 of the 11-upside having higher than the 3-month average volume with the increased volume of 5 of 22-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 11-upside were +0.41% (NTLA) to +5.61% (SLDB) while the 22-downside ranges from -0.06% (SAGE) to -5.55% (FIXX);

 

Hammered in today’s market:

  • Ultragenyx (RARE), Alnylam Pharmaceuticals (ALNY), Fate Therapeutics (FATE), CRISPR Therapeutics (CRSP), uniQure NV (QURE), to name 5 of the 22 declining of the 35 covered

Jumping with share pricing momentum:

  • Cellectis SA (CLLS), Global Blood Therapeutics (GBT), BioLife Solutions (BLFS), Intellia Therapeutics (NTLA), BioLife Solutions (BLFS), Solid Biosciences (SLDB) to name 5 of the 11 inclining of the 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed down -1.31% and XBI closed down -1.85%
  • Tuesday, the IBB closed up +0.48% and XBI closed up +1.37%
  • Monday, the IBB closed up +0.79% and XBI closed up +0.25%

 

Wednesday’s (10 of 10) incliners:

  • Cellectis SA (CLLS +$1.07 and Tuesday’s +$0.64);
  • Global Blood Therapeutics (GBT +$0.29 after Tuesday’s +$2.68 and Monday’s -$3.83);
  • BioLife Solutions (BLFS +$0.23 after Tuesday’s -$0.26 and Monday’s -$0.89);
  • Solid Bioscience (SLDB +$0.21 after Tuesday’s -$0.12 and Monday’s -$0.10);
  • Adverum Biotechnologies (ADVM +$0.15 after Tuesday’s +$0.46);
  • Vericel (VCEL+$0.12 after Tuesday’s -$0.77 and Monday’s -$0.12);
  • Bellicum Pharmaceuticals (BLCM +$0.11 after Tuesday’s -$0.07 after Monday’s -$0.22);
  • Intellia Therapeutics (NTLA +$0.10 after Tuesday’s +$0.70 and Monday’s -$2.40);
  • Voyager therapeutics (VYGR +$0.08);
  • Biostage (BSTG +$0.02);

Wednesday’s (10 of 22) decliner:

  • Ultragenyx (RARE -$4.71 after Tuesday’s +$1.90 and Monday’s +$1.05);
  • Alnylam Pharmaceuticals (ALNY -$2.75 after Tuesday’s -$0.34)
  • Fate Therapeutics (FATE -$2.08 after Tuesday’s +$0.29 and Monday’s +$1.02),
  • CRISPR Therapeutics (CRSP -$1.69 after Tuesday’s +$3.66 and Monday’s +$1.14);
  • uniQure NV (QURE -$1.00 after Tuesday’s -$0.51);
  • bluebird bio (BLUE -$0.96 after Tuesday’s -$1.64 and Monday’s +$0.79);
  • Homology Medicine (FIXX -$0.63);
  • Editas Medicine (EDIT -$0.61 after Tuesday’s +$0.55 and Monday’s- $0.87);
  • Regenxbio (RGNX -$0.49 after Tuesday’s -$0.98 and Monday’s +$0.40);

Closing flat –2 – ReNeuron (RENE.L) and Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Wednesday’s percentage (%) of the 11-upside were +0.41% (NTLA) to +5.61% (SLDB) while the 22-downside ranges from -0.06% (SAGE) to -5.55% (FIXX);
  • Tuesday’s percentage (%) of the 20-upside were +0.25% (MESO) to +4.58% (GBT) while the 12-downside of -0.23% (ALNY) to -4.78% (PGEN);
  • Monday’s percentage (%) of the 16-upside were +0.44% (QURE) to +5.92% (AXGN) while the 16-downside of -0.52% (ATHX) to -11.78% (PGEN);

 

Sentiment and a few daily indicators:

Daily new U.S. cases of the coronavirus, as a seven-day average, topped 50,000 for the first time in nearly two months. Average daily new infections are 16% higher than a week ago, and have been growing for the last nine days.

Infection cases <Million>:

  • Wednesday 7.86 M cases
  • Tuesday 7.8 M cases
  • Monday 7.77 M cases

Wednesday’s death rate totaled 215,971 after Tuesday’s 215,101, Monday’s 214,882, Friday’s 212,789, Thursday’s 211,844 and last Wednesday’s 210,918 <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Wednesday: 5 out of the 11-upside had higher than the 3-month average volume;
  • Tuesday: 3 out of the 20-upside had higher than the 3-month average volume;
  • Monday: 3 out of the 16-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +0.33 points or +1.27% at 26.40
  • Tuesday was up +1 points or +3.99% at 26.07
  • Monday was up +0.07 points or +0.28% at 25.07

Downside volume:

  • Wednesday: 5 out of the 22-downside had higher than the 3-month average volume;
  • Tuesday: 0 out of the 12-downside had higher than the 3-month average volume;
  • Monday: 3 out of the 16-downside had higher than the 3-month average volume;

 

October, the first month <October> of Q4 …

Wednesday closed negative with 11 advancers, 22 decliners and 2 flats 

Tuesday closed positive with 20 advancers, 12 decliners and 3 flats 

Monday (10/12) closed neutral with 16 advancers, 16 decliners and 3 flats 

Friday closed positive with 21 advancers, 9 decliners and 5 flats 

Thursday closed positive with 18 advancers, 14 decliners and 3 flats

Wednesday closed positive with 26 advancers, 9 decliners and 2 flats 

Tuesday closed negative with 11 advancers, 23 decliners and 1 flat 

Monday (10/5) closed positive with 33 advancers, 1 declined and 1 flat 

Friday closed negative with 8 advancers, 26 decliners and 1 flat 

Thursday (10/1) closed negative with 21 advancers, 12 decliners and 2 flats

 

The Bottom Line: The coronavirus pandemic has left its imprint on just about everything and vulnerable to bad news as Covid-19 cases continue spike in some areas.

While hopes for near-term stimulus have faded as Democrats and Republicans remain at odds.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.